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Introduction
Apo E is a 34-kDa plasma protein important for the
metabolism of plasma lipoproteins (1). Like other
apolipoproteins, apo E contains multiple 22–amino acid
repeats that form amphipathic helices, enabling it to
associate with the surface of plasma lipoproteins. Apo E
also contains a stretch of basic residues (136–150) that
is important for high-affinity binding to the LDL recep-
tor and subsequent endocytosis of the associated
lipoprotein particle (2). In addition, apo E mediates
lipoprotein interactions with LDL receptor–related pro-
tein (LRP) (3), the VLDL receptor (4), other lipoprotein
receptors (5), endothelial heparin sulfate (6), and plasma
lipases (7, 8). The phenotype of severe hyperlipidemia
and spontaneous development of atherosclerosis in mice
lacking apo E clearly demonstrates the central role of
apo E in mammalian lipid metabolism (9, 10).
In humans, the APOE gene is polymorphic and has 3
alleles: APOE*2, APOE*3, and APOE*4. These alleles have
frequencies of 7%, 77%, and 15%, respectively, in the gen-
eral population (11). The APOE*3 allele codes for cys-
teine at position 112 and for arginine at 158. The
APOE*2 allele codes cysteines at both positions, where-
as the APOE*4 allele codes for arginines at both posi-
tions. Various population-based studies have suggested
that the different APOE alleles have distinct influences
on lipid metabolism in humans. Possession of at least 1
copy of the APOE*2 allele has been associated with high-
er plasma apo E (12) and lower plasma cholesterol, LDL
cholesterol, and apo B levels (11) when compared with
APOE*3 homozygotes. The APOE*2 allele is also associ-
ated with lower risk of coronary artery disease (13),
except in 5–10% of APOE*2 homozygotes who develop
type III hyperlipoproteinemia and premature athero-
sclerosis (14). On the other hand, the presence of at least
1 APOE*4 allele is associated with lower plasma apo E
(12) and increased plasma cholesterol, LDL cholesterol,
and apo B levels (11), and a greater risk of coronary
artery disease (13), when compared with APOE*3
homozygotes. Davignon et al. (11) estimate that the apo
E polymorphism accounts for 2.8% of the variation of
risk for atherosclerosis, which is a large contribution for
a single locus in this complex, polygenic disease.
The availability of a well-defined model system should
benefit studies of the role of the human apo E polymor-
phism in lipid metabolism and atherosclerosis. To devel-
op such a model, we have used gene targeting to replace
the murine Apoe gene with the 3 human APOE alleles.
These mice retain the murine Apoe regulatory sequences
and solely produce human apo E proteins with different
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We have generated mice expressing the human apo E4 isoform in place of the endogenous murine apo
E protein and have compared them with mice expressing the human apo E3 isoform. Plasma lipid and
apolipoprotein levels in the mice expressing only the apo E4 isoform (4/4) did not differ significantly
from those in mice with the apo E3 isoform (3/3) on chow and were equally elevated in response to
increased lipid and cholesterol in their diet. However, on all diets tested, the 4/4 mice had approximately
twice the amount of cholesterol, apo E, and apo B-48 in their VLDL as did 3/3 mice. The 4/4 VLDL com-
peted with human LDL for binding to the human LDL receptor slightly better than 3/3 VLDL, but the
VLDL clearance rate in 4/4 mice was half that in 3/3 mice. On an atherogenic diet, there was a trend
toward greater atherosclerotic plaque size in 4/4 mice compared with 3/3 mice. These data, together
with our earlier observations in wild-type and human APOE*2-replacement mice, demonstrate a direct
and highly significant correlation between VLDL clearance rate and mean atherosclerotic plaque size.
Therefore, differences solely in apo E protein structure are sufficient to cause alterations in VLDL resi-
dence time and atherosclerosis risk in mice.
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primary structures. Previously, we reported mice homozy-
gous for the human APOE*3 (15) and APOE*2 (16) alle-
les (referred to as 3/3 and 2/2 mice, respectively) in place
of the coding sequences of the murine Apoe gene. The tis-
sue apo E mRNA distribution and levels in the 3/3 mice
were similar to the distribution and levels of murine apo
E mRNA in wild-type mice. The 3/3 mice on regular
mouse chow had normal plasma lipid profiles; however,
when fed a high-fat diet containing cholate (HFC), the
3/3 mice proved more susceptible to diet-induced lipemia
and atherosclerosis than did wild-type mice. On the other
hand, all the 2/2 mice exhibited features of type III hyper-
lipidemia, with 2.5 times the plasma total cholesterol and
triglycerides of wild-type mice, in addition to sponta-
neous atherosclerotic lesion formation, even on a normal
chow diet — regardless of age or sex.
In the present study, the plasma lipoproteins and risk
of atherosclerosis in mice homozygous for the APOE*4
allele (4/4 mice) and in 3/3 and 2/2 mice are compared.
We show that the 4/4 mice have increased steady-state
levels of non-HDL lipoproteins due mainly to reduced
VLDL plasma clearance. A direct and highly significant
correlation between the VLDL plasma residence time
and the extent of atherosclerosis is seen in mice express-
ing the different apo E isoforms. These results show that
the differences in apo E protein structure in the common
human isoforms alone are sufficient to cause differing
VLDL clearance rates and atherosclerosis risk in mice.
Methods
Generation of mice expressing human apo E4. Replacement of the
mouse Apoe gene with the human APOE*4 allele was achieved
in mouse embryonic stem cells as described previously (15),
except that the targeting construct contained exons 2–4 of
APOE*4 instead of APOE*3. Germ-line transmission of the
modified gene was achieved as described (15). All the mice used
in this study were F2-generation hybrids between 129 ×
C57BL/6 from 8 to 20 weeks of age unless otherwise stated.
Genotypes were determined using Southern blotting (15) or an
allele-specific PCR approach as described (17). Animals were
maintained on normal chow containing 4.5% fat and 0.022%
cholesterol (Prolab Isopro Rat/Mouse/Hamster 3000; catalog
no. 5P76; Agway Inc., Syracuse, New York, USA), or were fed an
atherogenic diet (HFC) containing 15.8% fat, 1.25% cholesterol,
and 0.5% sodium cholate (TD 88051; Harlan Teklad, Madison,
Wisconsin, USA) or a high-fat Western-style diet (HFW) con-
taining 21% fat and 0.2% cholesterol (TD 88137; Harlan
Teklad). The animals were handled under
protocols approved by the Institutional
Animal Care and Use Committees of the
University of North Carolina–Chapel Hill.
Plasma lipid and lipoprotein analysis. Plas-
ma was isolated, and total cholesterol (free
and esterified) and triglycerides were
measured as described previously (15).
HDL cholesterol was measured according
to Warnick et al. (18). VLDL was isolated
by ultracentrifugation at a density of
1.006 g/mL from either 1 mL of plasma
pooled from mice of identical apo E geno-
type or 200 µL of plasma from individual
mice. LDL was isolated after removing the
VLDL fraction by spinning at a density of
1.063 g/mL. Total lipoproteins were iso-
lated at a density of 1.21 g/mL. Lipopro-
tein fractions were dialyzed against PBS. Plasma (100 µL)
pooled samples were fractionated by fast protein liquid chro-
matography (FPLC) using a Superose 6 HR10/30 column
(Pharmacia Biotech Inc., Piscataway, New Jersey, USA). Apo E
was measured using an ELISA with antibodies specific for
human apo E as described (19). Apo B-100 levels were measured
using an ELISA with a primary apo B-100 mAb from a hybrido-
ma cell line kindly supplied by S. Young (Gladstone Institute,
University of California–San Francisco, San Francisco, Califor-
nia, USA) and a secondary polyclonal apo B antibody kindly
supplied by H. de Silva (University of North Carolina–Char-
lotte, Charlotte, North Carolina, USA). Apo B-100/apo B-48
ratios were determined by densitometry of bands of SDS-PAGE
of total plasma lipoproteins followed by Coomassie brilliant
blue staining. Isoelectric focusing of whole plasma was per-
formed according to the method of Hackler et al. (20). Electron
microscopy of isolated VLDL was done according to the
method of Forte and Nordhausen (21). Female mice were used
for these analyses unless otherwise stated.
LDL receptor binding and particle internalization  assay. The bind-
ing and internalization of VLDL via the human LDL receptor
were assayed using a modification of the competition method of
Goldstein and Brown (22) and Weisgraber et al. (23), using
human LDL labeled with 1,1′-dioctadecyl-3, 3, 3′, 3′-
tetramethylindocarbocyanine perchlorate (DilC18; Molecular
Probes Inc., Eugene, Oregon, USA), as described by Stephan and
Yurachek (24). VLDL was isolated by ultracentrifugation from
female mice of each genotype maintained on an HFC diet. Pro-
tein concentrations were determined using a colorimetric assay
(Bio-Rad Laboratories Inc., Richmond, California, USA). Immor-
talized human fibroblast cells (kindly provided by J. Herz, Uni-
versity of Texas–Southwestern, Dallas Texas, USA) were grown in
24-well plates with DMEM and 10% FBS to 90% confluence. The
medium was replaced with DMEM containing 0.5% BSA at 24
hours before the experiment. Labeled human LDL (50 µg/mL)
was added to each well, along with increasing amounts of murine
VLDL, ranging from 0.5 µg/mL up to 100 µg/mL. Cells were
incubated at 37°C to determine cellular association and inter-
nalization of particles. After incubation, the media were removed,
cells were washed 4 times with PBS, and fluorescence was meas-
ured with excitation and emission wavelengths of 520 nm and
578 nm, respectively. Cell number was normalized between plates
and between experiments by total protein concentration of rep-
resentative wells. The average of 4 wells was used for each data
point, and values for Ki were determined by averaging the results
of 3 experiments carried out at 37°C.
VLDL clearance assay. Clearance rate of VLDL from the circu-
lation of 3/3 and 4/4 mice was determined as described previ-
ously (15), using [14C]cholesterol-labeled VLDL (d < 1.010) iso-
lated from apo E knockout mice on normal chow or from 3/3
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Table 1
Plasma lipid and apo E concentrations in the 3/3 and 4/4 mice
Genotype Diet TC TG HDL-C Apo E
mg/dL mg/dL mg/dL mg/dL
NC 75 ± 26 (30) 52 ± 26 (30) 61 ± 24 (12) 1.2 ± 0.5 (6)
3/3 HFC 363 ± 97 (11) 16 ± 11 (11) 25 ± 8 (11) 13.6 ± 8.6 (11)
HFW 122 ± 43 (7) 48 ± 4 (7) 107 ± 38 (7) 1.8 ± 0.3 (6)
NC 72 ± 27 (30) 49 ± 22 (30) 58 ± 22 (12) 1.6 ± 0.7 (6)
4/4 HFC 380 ± 64 (11) 18 ± 2 (11) 20 ± 10 (11) 11.7 ± 3.8 (11)
HFW 130 ± 27 (6) 66 ± 31 (6) 74 ± 18 (6) 3.0 ± 1.3 (4)
Data are means ± SD of fasted female mice receiving chow (NC) high-fat cholate (HFC), or high-fat western
(HFW) diets. Parentheses show number of mice analyzed. No values were significantly different between geno-
types on equel diets. TC, total cholesterol; TG, triglycerides; HDL-C, HDL cholesterol.
or 4/4 mice on normal chow. The fractional catabolic rates and
their variances were determined as described previously using
a two-compartment model (25). Three age-matched males of
each genotype were used for each experiment.
Triglyceride secretion assay. Triglyceride secretion rate was deter-
mined according to the procedure of Li et al. (26). Briefly,
female mice of each genotype on normal chow were fasted for
4 hours. The 4/4 mice were F2 generation, and the 3/3 mice
were F3 generation and were age matched between 8 and 20
weeks of age. Plasma was collected for triglyceride measure-
ments at time 0 and at 30, 60, and 120 minutes after injection
of Tyloxapol (Triton WR-1339; Sigma Chemical Co., St. Louis,
Missouri, USA) via tail vein at a dose of 0.7 mg/g body weight.
At 5 hours, the animals were exsanguinated and total liver
weight was measured. Rates of triglyceride secretion were cal-
culated, normalized for liver weight, and expressed as mil-
ligrams of triglyceride per hour, assuming that the plasma vol-
ume of mice is 4.5% of body weight.
Evaluation of atherosclerotic lesions. Female mice were fed an
atherogenic diet (HFC) for 3 months before sacrifice. Athero-
sclerotic plaque sizes in aortic root sections were determined as
described previously (27).
Statistical analysis. The significance of differences between
means was calculated by using either a two-tailed unpaired Stu-
dent t test or one-way ANOVA followed by Tukey-Kramer Hon-
estly Significant Difference test (JMP software; SAS Inc., Cary,
North Carolina, USA).
Results
Production of functional apo E4 in mice with human APOE*4.
Mice in which the murine Apoe gene was replaced with
the human APOE*4 allele were generated using proce-
dures described previously (15). Targeted modification of
the locus was confirmed at the DNA level by Southern
blotting and by the presence of APOE*4-specific frag-
ments in PCR followed by HhaI digest of the genomic
DNA isolated from mouse tails (data not shown). Sepa-
ration of plasma proteins via isoelectric focusing, which
distinguishes the 3 human apo E isoforms by their charge
differences due to differing arginine content, revealed
that the apo E4 protein in the mice homozygous for the
modified gene (4/4) is indistinguishable from human
apo E4 standards (Figure 1a). Thus, the apo E4 protein
expressed in 4/4 mice was the same charge and size as the
apo E4 protein isolated from human plasma.
Expression of functional apo E4 protein was determined
by assessing the capacity of VLDL from the 4/4 mice to
bind to the human LDL receptor using an in vitro com-
petition assay. VLDL was isolated from 4/4, 3/3, or 2/2
mice maintained on an HFC diet and was used to compete
with human LDL labeled with a lipophilic fluorescent dye
(DilC18) for binding to, and internalization by, the LDL
receptor on human fibroblasts (24). The results shown in
Figure 1b demonstrate that the apo E4 in VLDL from the
4/4 mice and apo E3 in VLDL from the 3/3 mice both
compete well with human LDL for binding and uptake by
the human LDL receptor. Ki determined from 3 repeated
experiments, each consisting of quadruple measurements,
were 3.6 ± 0.6 mg for 4/4 VLDL and 5.7 ± 1.12 mg for 3/3
VLDL (P = 0.05 by one-way ANOVA). Therefore, the 4/4
VLDL has the ability to compete with human LDL for
binding to the human LDL receptor better than the 3/3
VLDL. Apo E2 in the VLDL from the 2/2 mice competes
poorly with human LDL for binding to the human LDL
receptor (Ki = 69 ± 8 mg; P < 0.01 vs. 3/3). These data
demonstrate that the ability of VLDL to compete with
labeled LDL for cellular binding and internalization
increases in the 3 lines of mice in the order 4/4 > 3/3 > 2/2.
Increased non-HDL lipoproteins in 4/4 mice. In humans,
APOE*4 is associated with increased plasma and LDL
cholesterol (11). We therefore examined plasma lipid and
apolipoprotein levels in the 4/4 mice and compared
them with those in the 3/3 mice. On all diets tested, total
plasma cholesterol, triglycerides, HDL-cholesterol, and
apo E protein amount did not differ significantly
between the 2 genotypes. Table 1 presents the values for
female mice. Chow-fed male mice had higher plasma
lipid levels than females did, but there were no genotype-
dependent differences (data not shown). These data indi-
The Journal of Clinical Investigation | June 1999 | Volume 103 | Number 11 1581
Figure 1
(a) Mice with the 3 human apo E isoforms. Delipidated plasma samples
from 2/2 (lane 2), 3/3 (lane 3), and 4/4 (lane 4) mice were separated
by isoelectric focusing, and the apo E proteins were viewed by silver
staining after immunofixation with an anti-human apo E antibody. The
positions of the human apo E isoforms — E2, E3, and E4 — are indicat-
ed. Lane 1 shows apo E2, apo E3, and apo E4 from mixed human plas-
ma as controls. (b) Competition assay of human LDL receptor binding
and internalization of VLDL from 2/2, 3/3, and 4/4 mice. VLDL was iso-
lated from 2/2 (filled squares), 3/3 (filled circles), and 4/4 (open trian-
gles) mice maintained on an HFC diet by ultracentrifugation of plasma
pooled from at least 6 animals, and it was used to compete with DiIC18-
labeled  human LDL for binding to human fibroblasts. Values are the
mean – SD of 4 wells from a representative experiment carried out at
37°C. VLDL amounts are expressed as micrograms of total protein. The
apo E content of the isolated VLDL was approximately 17 ± 3%, 7 ± 3%,
and 4 ± 1% of total protein for 2/2, 3/3, and 4/4 VLDL, respectively (P
< 0.001 by one-way ANOVA).
cate that the 4/4 and 3/3 mice maintain normal plasma
lipid levels on chow diet and that both lines are equally
susceptible to HFC diet–induced hyperlipidemia.
Although overall plasma lipid levels are similar between
the 3/3 and 4/4 mice on normal chow, the distribution of
lipid in various lipoprotein fractions was different. FPLC
analysis of plasma from 4/4 mice showed that the
amounts of cholesterol, triglyceride, and apo E were slight-
ly greater in the VLDL fractions (fractions 14–16), where-
as they were slightly less in the HDL fractions (fractions
26–30), compared with 3/3 mice (Figure 2, a–c). The
increase in VLDL cholesterol in 4/4 mice compared with
3/3 mice was also seen on an HFW diet (Figure 2f) and an
HFC diet (Figure 2g). On the other hand, the cholesterol
in other particles (IDL, LDL, and HDL) was slightly
reduced in 4/4 mice compared with 3/3 mice on an HFC
diet (Figure 2g). Ultracentrifugation of plasma confirmed
these results, with a statistically significant (P < 0.05) high-
er level of VLDL cholesterol in 4/4 mice maintained on an
HFW or HFC diet compared with 3/3 mice on similar
diets (Figure 3). Ultracentrifugation also showed that on
normal chow, there was a significantly greater choles-
terol/triglyceride ratio in 4/4 VLDL compared with 3/3
VLDL (0.87 ± 0.45 in 4/4 vs. 0.33 ± 0.5 in 3/3; P < 0.01).
The cholesterol levels in the LDL fraction on all diets did
not differ significantly between the 2 groups of mice.
There was no marked difference in relative apolipopro-
tein composition in lipoprotein fractions isolated by
ultracentrifugation from 4/4 and 3/3 mice on normal
chow by SDS-PAGE analysis (data not shown). However,
amounts of apo E and apo B-48 (by SDS-PAGE; Figure
2e) in the VLDL fraction of 4/4 mice were approximately
twice those of the 3/3 mice. Plasma total apo B-100 levels
determined by ELISA were not significantly different
between the 4/4 or 3/3 mice (7.4 ± 1.6 in the 3/3 mice and
9.1 ± 4.4 in the 4/4 mice; arbitrary units, n = 6). The high
apo B-48 in the VLDL of 4/4 mice results in differences in
the apo B-100/apo B-48 ratios between these animals (0.7
in 4/4 mice compared with 1.2 in 3/3 mice on normal
chow). Taken together, these results show that on normal
chow, 4/4 mice have a 2-fold greater amount of apo B-
48–containing VLDL particles compared with 3/3 mice.
Increased diameter of 4/4 VLDL particles. To determine
whether the increase in lipids and apolipoproteins in
the 4/4 VLDL is due to differences in the size of the par-
ticles, we examined the diameter of the VLDL particles
by electron microscopy. VLDL was isolated by ultracen-
trifugation from plasma pooled from 4 female mice of
each genotype maintained on normal chow. There was
a significant increase in diameter of VLDL from the 4/4
mice (43 ± 13 nm; mean ± SD, n = 416) compared with
the 3/3 mice (41 ± 14 nm; n = 270, P < 0.05 vs. 4/4) and
2/2 mice (36 ± 11 nm; n = 358, P < 0.01 vs. 3/3). The frac-
tion of VLDL larger than 45 nm in diameter in the 4/4
mice was 39% compared with 31% and 17% in the 3/3
and 2/2 mice, respectively. Approximately 9% of parti-
cles from 4/4 and 3/3, but only 4% of the particles from
2/2, mice had a diameter larger than 60 nm. This analy-
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Figure 2
Distribution of plasma lipoproteins, apo E, and apo B-100 in mice fed normal chow (a–e), HFW (f), and HFC (g). Pooled plasma (100 µL) from 6
age-matched female mice was fractionated by gel filtration chromatography on a Superose 6B column, and 0.5-mL fractions were collected. Frac-
tions containing VLDL, IDL/LDL, and HDL are shown. (a) Total cholesterol was measured in micrograms per fraction. (b) Triglycerides were meas-
ured in micrograms per fraction. (c) Apo E (micrograms per fraction) was measured using an ELISA with antibodies specific for human apo E. (d)
Apo B-100 was measured using an ELISA with antibodies specific for mouse apo B-100 and is expressed as arbitrary units per fraction. (e) Apo B-
100 and apo B-48 of isolated VLDL (80 µL plasma equivalent) or total lipoproteins (25 µL plasma equivalent) from 3/3 and 4/4 mice were viewed
by Coomassie blue staining after SDS-PAGE on 3–20% gradient gel. (f) Total cholesterol was measured in micrograms per fraction in at least 5 female
mice maintained on an HFW diet for 2 months. (g) Total cholesterol was measured in micrograms per fraction in at least 5 female mice maintained
on an HFC diet for 2 months.
sis suggests that the VLDL particles of 4/4 mice have a
15% greater volume than 3/3 VLDL and, when taken
together with previous results, suggests that both the
size and number of VLDL particles are greater in the 4/4
animals. In contrast, the 2/2 VLDL particles have 25%
less volume compared with 3/3 VLDL particles. The
markedly greater triglycerides and cholesterol in the
VLDL fraction of the 2/2 mice compared with the 3/3
mice is therefore due to the former having a greater
number of VLDL particles. This suggests that there are
different mechanisms accounting for the observed high
levels of VLDL cholesterol in the 2/2 and 4/4 mice com-
pared with the 3/3 mice.
Delayed VLDL clearance in 4/4 mice. To understand the
basis for differences between steady-state VLDL levels in
the plasma of 4/4 mice and 3/3 mice, the clearance rate
of [14C]cholesterol-labeled VLDL introduced into these
mice was analyzed. The clearance of injected apo E–defi-
cient VLDL was slower in 4/4 mice compared with 3/3
mice fed a normal chow diet (Figure 4a), with a fraction-
al catabolic rate of 0.6 ± 0.06 pools/h in the 4/4 mice
compared with 1.2 ± 0.07 pools/h in the 3/3 mice (n = 5,
P < 0.001). Even though the clearance rate was less in the
4/4 mice, the levels of labeled VLDL were reduced to
baseline by 4 hours, whereas those in the 3/3 mice were
reduced to baseline by 2 hours.
The differences in clearance of apo E–deficient VLDL
could be due to differences in the ability of plasma apo
E proteins to be transferred from endogenous VLDL to
the injected apo E–deficient VLDL particles. We there-
fore repeated the experiments using labeled VLDL from
donors of the same genotype as the recipients. A simi-
larly low fractional catabolic rate (0.8 ± 0.08 pools/h) was
observed in 4/4 mice compared with 3/3 mice (1.5 ± 0.3
pools/h; n = 5, P < 0.05) when VLDL obtained from 4/4
or 3/3 donor mice was injected into homologous recipi-
ent mice (Figure 4b). Additionally, the initial clearance
rate (less than 2 minutes) was significantly faster for
homologous donor VLDL than for apo E–deficient
donor VLDL for both genotypes (P < 0.05).
In a preliminary experiment, we also labeled lipopro-
teins in 3/3 or 4/4 mice and then isolated and injected
the labeled VLDL into 2 mice of the opposite genotype,
i.e., 3/3 VLDL into 4/4 mice and 4/4 VLDL into 3/3
mice. The clearance was again slower in the 4/4 mice
than in 3/3 mice, and the clearance rate was similar to
the homologous VLDL (data not shown). These results
show that 4/4 mice have a significantly impaired abil-
ity to clear VLDL particles from their plasma relative
to 3/3 mice and that the genotype of the recipient
mice, not that of the donor VLDL, determines the
clearance rate.
Steady-state levels of VLDL may also be influenced by
its secretion. Therefore, we investigated the secretion rate
of triglycerides in all lines of mice, using Triton WR-1339
to block lipolysis and uptake of VLDL. There was no dif-
ference in the triglyceride secretion rate between the 4/4
mice (3.20 ± 0.47 mg/h/g liver; n = 7) and 3/3 mice (3.22
± 0.33 mg/h/g; n = 9). These data suggest that the
increase in steady-state levels of VLDL in the 4/4 mice
results mainly from the reduction of plasma VLDL clear-
ance and not by increased VLDL secretion.
Morphometric evaluation of aortic lesions. The greater non-
HDL lipoprotein levels in the 4/4 mice compared with
the 3/3 mice suggest that 4/4 mice may also be more sus-
ceptible to atherosclerosis. We therefore fed female 3/3
and 4/4 mice an atherogenic diet (HFC) for 3 months to
assess atherosclerotic lesion development in the proxi-
mal aorta near the aortic root. The mean lesion size in
the 4/4 mice (14.7 ± 8.9 × 104 µm2; n = 17) was twice as
large as in 3/3 mice (7.7 ± 5.0 × 104 µm2; n = 12, P = 0.11).
The large variation in plaque size developing in the F2
animals precluded this difference from reaching statis-
tical significance (P = 0.11), but there already is a trend
of increased lesion size in the 4/4 mice. This increase in
lesion size in 4/4 mice compared with 3/3 mice correlates
with the increased steady-state VLDL cholesterol and the
decreased VLDL fractional catabolism in 4/4 mice com-
pared with the 3/3 control mice.
The availability in mice of 4 allelic forms of apo E with
varied structure enables us to examine how these alleles
correlate with atherogenesis. The present data on the 4/4
and 3/3 mice were combined with previously reported
data on wild-type, 2/2, and 3/3 mice and are summarized
in Figure 5. There is a clear hierarchy in the order of 2/2
> 4/4 > 3/3 > wild-type in both plasma residence time of
labeled VLDL (inverse of the fractional catabolic rate)
and in the size of atherosclerotic plaques. Furthermore,
the correlation between mean lesion size observed in
each group of mice with mean VLDL residence time was
high and significant (r2 = 0.981, P < 0.01). These results
demonstrate the importance of apo E as a primary deter-
minant of the plasma residence time of atherogenic
lipoproteins and the effect of VLDL clearance rate on the
extent of atherosclerotic lesions.
Discussion
In this study, we have compared the in vivo effects of the
human apo E4 isoform with the effects of the human apo
E3 and apo E2 isoforms on both lipoprotein metabolism
and atherogenesis in mice. The mice compared are genet-
ically equivalent, except at the coding regions of their Apoe
gene. They have the normal murine regulatory regions
intact and exclusively express 1 of the 3 common human
apo E isoforms in a physiologically regulated manner. We
find that steady-state plasma lipid levels in both the 4/4
and 3/3 mice are significantly lower than the levels in 2/2
mice, although they are not significantly different from
each other on normal chow. However, there are subtle but
notable differences in lipoprotein distribution between
the 4/4 and 3/3 mice. The 4/4 mice have about twice the
level of cholesterol, apo E, and apo B-48 in the VLDL frac-
tion compared with 3/3 mice. The 4/4 VLDL particles
have a 15% greater mean volume than the 3/3 VLDL par-
ticles, which in turn have a 25% greater volume than the
2/2 VLDL particles. We find by direct measurement a 2-
fold reduction in the VLDL clearance rate in the 4/4 mice
compared with the 3/3 mice. This reduced clearance
appears to be the main determinant of the increase in the
steady-state levels of VLDL, as the VLDL secretion rates in
the 2 groups of mice were not different.
The apo E4 isoform expressed in the mice we have gen-
erated is indistinguishable from that in humans at the
DNA level and protein level. Furthermore, the apo E4 in
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the 4/4 mice is completely functional, as assessed by the
demonstrated ability of VLDL from these mice to compete
with human LDL for binding to the human LDL receptor.
Therefore, the observed effects of apo E4 on lipid metab-
olism in mice are unlikely to be due to any inadvertent
modifications of the APOE gene or its products intro-
duced during the generation of the mice. The 4/4 VLDL
competed with human LDL for binding to the human
LDL receptor slightly better (150%) than VLDL isolated
from 3/3 mice. The 2/2 VLDL competed with human LDL
for binding to the human LDL receptor significantly
worse (<10%) than 3/3 VLDL. The hierarchy of LDL recep-
tor–binding affinity of the 3 apo E isoforms expressed in
the mice agrees with the results by Bohnet et al. (28), who
used labeled VLDL isolated from human subjects with the
different apo E isoforms and showed that apo E4–con-
taining particles had the highest affinity (122%) for the
LDL receptor, followed by apo E3–containing particles
(100%) and apo E2–containing particles (37%). Similarly,
Weisgraber et al. (23) showed that purified apo E2 recon-
stituted with dimyristoylphosphatidylcholine disks has
only 1% the affinity of apo E3 for the LDL receptor.
Although, as in humans with APOE*4 and APOE*3, the
4/4 mice have more non-HDL particles and slightly less
HDL compared with the 3/3 mice, there are some differ-
ences between the observations in humans and mice.
Most notably, in the 4/4 mice the majority of non-HDL
cholesterol is in the VLDL fraction, not the LDL fraction
as in humans. Furthermore, substantially more apo B-48
is present in the 4/4 mice compared with the 3/3 mice, and
this increase in apo B-48 was not accompanied by any
change in the apo B-100 levels. These differences are not
surprising given that in mice, but not in humans, about
70% of the apo B mRNA is edited in the liver (29). This
results in production of apo B-48–containing VLDL by
the liver in mice, whereas human liver produces only apo
B-100–containing VLDL. Apo B-48–containing lipopro-
tein particles are processed differently than apo B-
100–containing particles; the former requires apo E for
receptor binding and has a much shorter plasma half-life
than the latter (30). Consequently, mice have a greater
dependence on apo E proteins for lipoprotein clearance
than humans. The hepatic output of apo B-48 likely con-
tributes to the severe type III hyperlipidemia in the 2/2
mice and the preferential accumulation of apo B-48–con-
taining particles over apo B-100–containing particles in
4/4 mice, both being exaggerated phenotypes compared
with humans. Additionally, we note that species differ-
ences in lipid metabolism between mice with human apo
E isoforms and humans may also result from the fact that
the human protein in mice has to interact with many
murine proteins, and these interactions may not neces-
sarily be identical to those occurring in humans.
A long-standing hypothesis advanced to explain the
metabolic effects of different apo E isoforms is that dif-
ferences in apo E isoform LDL receptor–binding affini-
ty result in differences in hepatic LDL receptor levels
(11). According to this hypothesis, the lower LDL recep-
tor affinity of apo E2 decreases cellular cholesterol
influx, and the resulting smaller intracellular sterol
pools lead to upregulation of the LDL receptor. The
effects of apo E4 are less clear, but it has been hypothe-
sized that the LDL receptor is downregulated in individ-
uals with an APOE*4 as a result of an enhanced uptake
of apo E–containing VLDL remnants (31, 32). However,
we find that remnant clearance in our 4/4 mice is slower
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Figure 4
The plasma clearance of VLDL in 3/3
and 4/4 mice. Three male mice main-
tained on normal chow of each group
(filled circles, 3/3; open triangles, 4/4)
were injected with radiolabeled remnant
particles from apo E–deficient donor
mice (a) or from donor mice of the same
genotype (b), and the fraction of
radioactivity remaining in plasma was
measured for 2 hours. Each data point
shows mean – SD. The SD of some data
is smaller than the data points.
Figure 3
VLDL cholesterol in 3/3 and 4/4 mice on 3 dif-
ferent diets. VLDL from plasma of 6 individual
female mice maintained on normal chow (a),
HFW diet (b), or atherogenic diet (HFC) (c) was
isolated by ultracentrifugation. Amounts are
expressed in milligrams of cholesterol per deciliter
of plasma ± SD (n = 6 for all groups).
than in the 3/3 mice. Furthermore, although the recep-
tor hypothesis predicts that reduced LDL receptor
expression causes an accumulation of apo B-100–con-
taining particles, we found no increase in apo B-100 LDL
in the 4/4 mice. Rather, there was an increase in apo B-
48 particles in the VLDL range in the 4/4 mice compared
with the 3/3 mice. Our results agree more with an alter-
native hypothesis proposed by Bergeron and Havel (33)
that the prolonged residence times of VLDL remnants in
persons carrying the APOE*4 allele raise the concentra-
tion of LDL by increasing the amount of VLDL convert-
ed to LDL. Normolipidemic male 4/3 subjects studied by
these investigators exhibited increased postprandial apo
B-48 and lipid levels compared with 3/3 subjects (33). An
increased conversion of VLDL to smaller remnants and
a relative decrease in direct removal of VLDL in E4
homozygotes compared with E3 subjects have also been
demonstrated by Demant et al. (34).
The delayed clearance of VLDL remnants in the 4/4
mice compared with the 3/3 mice appears to be due to
intrinsic differences in the recipient animals themselves
rather than their VLDL particles, as judged by our pre-
liminary results of introducing 4/4 particles into 3/3 mice
and 3/3 particles into 4/4 mice. It is therefore tempting to
speculate that the greater amount of VLDL in 4/4 mice
compared with 3/3 mice, and particularly the increase of
particles containing apo B-48 but not apo B-100, may be
related to the differential interaction of VLDL particles
with the hepatic microenvironment. For example, LRP is
important in clearing apo B-48–containing particles but
less so in clearing apo B-100–containing particles (35).
Various in vitro or tissue culture–based experiments have
suggested equal LRP-binding affinity as well as cholesterol
delivery to cells by lipoprotein particles with apo E4 and
apo E3 (3, 36). The implication of these observations for
in vivo VLDL remnant uptake is unclear, and there is evi-
dence that remnant clearance through LRP requires
hepatic apo E expression (37). It may be that there are iso-
form-specific differences in intracellular distribution of
apo E in hepatocytes that result in differences in LRP pro-
cessing. Alternatively, there may be isoform-specific dif-
ferences in hepatocyte apo E secretion, resulting in differ-
ences in secretion-capture of VLDL remnants. Cullen et al.
(38) have recently shown that the amount of apo E
released from the cell surface by suramin and heparinase
treatments is greater with macrophages expressing apo E4
than with those expressing apo E3. Isoform-specific dif-
ferences in hepatocyte distribution of apo E, and their
influence on receptor-mediated uptake of remnant parti-
cles, merit further investigation.
The present experiments impinge directly on the influ-
ence of apo E genotype on the development of athero-
sclerotic lesions after feeding an atherogenic diet. Our
data (presented in Figure 5) show a highly significant
relationship (P < 0.01) between the sizes of atheroscle-
rotic plaques in the aortic sinus of wild-type, 2/2, 3/3,
and 4/4 mice and plasma residence time of exogenously
introduced VLDL (inverse of the fractional catabolic
rate). Because the only systematic genetic difference
among these animals is at their Apoe locus, our experi-
ments enable us to establish unequivocally that the
structure of the apo E protein is the primary determi-
nant of atherosclerosis risk and of VLDL residence time
in these mice. We recognize that the exact relationships
between apo E isoform and atherosclerosis risk observed
in mice may not be directly transferable to humans.
Thus, the majority of human individuals homozygous
for APOE*2 show lower incidents of cardiovascular dis-
eases than those with other APOE genotypes (13). The
2/2 mice are similar to the fraction of human-3 APOE*2
homozygotes who display type III hyperlipidemia and
develop premature atherosclerosis. On the other hand,
our observation that the 4/4 mice tend to develop larger
plaques than the 3/3 mice on an atherogenic diet mirror
the findings in humans that possession of an APOE*4
allele is associated with higher risk for coronary disease
(13). Finally, the direct and highly significant correlation
between the plasma residence time of remnant particles
and the extent of atherosclerotic lesions seen in the mice
is clear experimental support for the hypothesis that any
prolongation of the half-life of non-HDL lipoprotein
increases the likelihood that it will be modified into
atherogenic forms (reviewed in ref. 39).
In conclusion, our study demonstrates that mice hav-
ing targeted replacements of the intrinsic murine Apoe
gene with the 3 human APOE alleles recapitulate many
of the phenotypic effects seen in humans with these
same isoforms. Furthermore, these mice provide direct
experimental proof that the degree of atherosclerosis is
correlated with the residency time of atherogenic
lipoproteins in the plasma and show that changes only
in the apo E protein structure are sufficient to determine
both the residency time of atherogenic lipoproteins in
plasma and the extent of lesions after feeding on an
atherogenic diet.
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